CHICAGO, Oct 8 (Reuters) - Final data from Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than previously reported preliminary data showed, the company and researchers said on Thursday. (Reporting by Julie Steenhuysen Editing by Chris Reese)
Our Standards: The Thomson Reuters Trust Principles.